Medical technology company Boston Scientific Corporation (NYSE: BSX) announced on Monday that it has entered into a definitive agreement to acquire Cortex Inc, a medical technology firm backed by Ajax Health.
This acquisition is aimed at enhancing Boston Scientific's electrophysiology portfolio.
Cortex specialises in advanced diagnostic mapping for atrial fibrillation (AF), a heart condition affecting nearly 38 million people globally. Its flagship OptiMap System, which received FDA 510(k) clearance in 2023, uses a proprietary basket catheter and algorithm to identify AF triggers beyond the pulmonary veins, providing precise insights for tailored cardiac ablation. Data from Cortex's FLOW-AF clinical trial shows that OptiMap-guided ablation improved freedom from AF by 51% over traditional pulmonary vein isolation alone. Additionally, the company has launched RESOLVE-AF, a 300-patient global trial to further assess OptiMap's efficacy in treating AF.
The acquisition is expected to close in the first half of 2025, pending customary conditions, with a minimal effect on Boston Scientific's adjusted earnings per share in 2025.
Financial terms remain undisclosed.
Johnson & Johnson seeks approval for DARZALEX FASPRO in smoldering multiple myeloma
FDA Panel supports IceCure's ProSense Cryoablation for early-stage breast cancer
Dizal submits NDA to US FDA for sunvozertinib in treating NSCLC with EGFR exon 20 mutations
Naitive Technologies enters strategic agreement with Parvizi Surgical Innovation
Akura Medical's application for trial of Katana Thrombectomy System receives US FDA approval
FDA accepts Ionis Pharmaceuticals' donidalorsen New Drug Application
Kazia Therapeutics secures FDA meeting to explore paxalisib pathways for glioblastoma
Boston Scientific to acquire Cortex Inc in strategic expansion of electrophysiology portfolio
Formosa Pharmaceuticals signs licensing agreement with DÁVI Farmaceutica
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation